Gastrointestinal Cancer

Influence of Alcohol Consumption on Survival Outcomes of Hepatocellular Carcinoma

Influence of Alcohol Consumption on Survival Outcomes of Hepatocellular Carcinoma

By

Results of the prospective CHANGH study demonstrate the effect of alcohol consumption on early diagnosis, management, and overall survival for patients with hepatocellular carcinoma.

Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers

Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers

By

Sexual impairment is frequently associated with breast and pelvic cancers, but patients with digestive cancer also experience this effect. In this study, researchers assessed sexual activity, dysfunction, sexual quality of life, and need for oncosexology care among patients with gastrointestinal cancers.

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

By

A multivariable analysis revealed how median household income influences cancer-specific and overall survival among patients with squamous cell carcinoma of the anus.

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

By

At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.

Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone

Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone

By

Double-blind phase 3 study evaluated the effect of megestrol combined with celecoxib vs monotherapy on cachexia in patients with gastrointestinal cancer.

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

By

Researchers conducted a retrospective study of US patients with gastric cancer to determine what factors influenced the use of preoperative chemotherapy in this patient population.

Comparative Study of Clinical Efficacy Using Three-dimensional and Two-dimensional Laparoscopies in the Treatment of Distal Gastric Cancer

Comparative Study of Clinical Efficacy Using Three-dimensional and Two-dimensional Laparoscopies in the Treatment of Distal Gastric Cancer

[OncoTargets and Therapy] This study investigated the safety and feasibility of 3D laparoscopic-assisted radical gastrectomy for distal advanced gastric cancer vs 2D laparoscopic surgery, results of this study have shown.

Recognizing Reduced Dietary Intake in Hospitalized Patients With Colorectal Cancer

Recognizing Reduced Dietary Intake in Hospitalized Patients With Colorectal Cancer

By

Analysis revealed factors that contribute to reduced dietary intake among hospitalized patients with colorectal cancer.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

By

Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy

Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy

[Journal of Thoracic Disease] A randomized study investigated whether an mERAS protocol could result in improved recovery of aged patients with esophageal cancer undergoing esophagectomy.

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

By

Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

By

Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.

PPI-Gastric Cancer Link Remains After <i>H. Pylori</i> Eradication

PPI-Gastric Cancer Link Remains After H. Pylori Eradication

Increased risk seen in H. pylori-infected subjects who received eradication therapy

Symptoms, Economic Burden Reduce QoL in Gastrointestinal Cancer Survivors

Symptoms, Economic Burden Reduce QoL in Gastrointestinal Cancer Survivors

By

A cross-sectional survey revealed the impact of symptoms and economic burden on quality of life for survivors of gastrointestinal cancer.

Childhood-Onset IBD May Increase Adult Cancer Risk

Childhood-Onset IBD May Increase Adult Cancer Risk

Researchers think chronic inflammation in gastrointestinal tract may increase the future risk of gastrointestinal cancers, lymphoid neoplasms, and skin cancer.

CAR, PNI Levels Correlate with Outcomes in Pancreatic Cancer

CAR, PNI Levels Correlate with Outcomes in Pancreatic Cancer

By

An association was found between low PNI/high CAR levels and poor outcomes in operable pancreatic ductal adenocarcinoma, even in patients who undergo curative resection.

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

By

A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

A new report from ACS describes trends in liver cancer and the factors influencing the ongoing increase in incidence, particularly higher rates of HCV infection, obesity, and type 2 diabetes.

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

By

Study compared FOLFOXIRI/bevacizumab and FOLFOX/bevacizumab in patients with metastatic colorectal cancer.

ACS Survivorship Guidelines for Healthy Behaviors Beneficial for Colon Cancer Survivors

ACS Survivorship Guidelines for Healthy Behaviors Beneficial for Colon Cancer Survivors

By

Patients with stage III colon cancer who follow the ACS guidelines for a healthy lifestyle after adjuvant chemotherapy had longer disease-free survival and overall survival.

Consuming Tree Nuts Improves DFS, OS in Survivors of Colon Cancer

Consuming Tree Nuts Improves DFS, OS in Survivors of Colon Cancer

By

Consumption of tree nuts is associated with significantly improved disease-free survival (DFS) and overall survival (OS) in survivors of stage III colon cancer who consume 2 or more servings per week.

Genome-Informed Treatment Improves Survival in Pancreatic Cancer

Genome-Informed Treatment Improves Survival in Pancreatic Cancer

By

Precision Medicine Improves Pancreatic Cancer Treatment

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

By

Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

By

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

SEER Data Illustrates Trends in Gallbladder Cancer Incidence, Stage at Diagnosis

SEER Data Illustrates Trends in Gallbladder Cancer Incidence, Stage at Diagnosis

By

Trends in SEER data from 1972 to 2009 show gallbladder cancer incidence decreasing in men, but late-stage disease at diagnosis for both sexes is increasing.

Survival Better for Hispanics, Blacks With Colorectal Cancer but HR-QoL Is Better for Whites

Survival Better for Hispanics, Blacks With Colorectal Cancer but HR-QoL Is Better for Whites

By

Although median survival is longer for Hispanic and black patients compared with white patients, health-related QoL is poor for minority patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs